DLL3, a non-canonical inhibitor of the Notch signaling pathway, exhibits unique molecular mechanisms that underpin its dual role in small cell lung cancer (SCLC) progression and therapeutic targeting. This evidence concerns the gene DLL3 and small cell lung carcinoma.